Date: July 28-30, 2021 ONLINE LIVESTREAM On July 28-30, 2021, medical officers and healthcare professionals are invited to attend DGE’s 4th Digital & Innovation For Medical Affairs Summit to learn and upskill with the progressive technologies and novel policies of the digital era. This online live streaming event is organized by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The COVID pandemic has paved way for enormous changes that both patients and HCPS are adapting to. The need for relevant, speedy, and precise scientific information is now greater than ever. The need of the hour is the complete transformation of medical affairs departments by incorporating new policies and patient-centricity demonstrating value to both internal and external stakeholders in a digital era. With this online conference, medical professionals can join our growing community of interactive participants who can learn the nitty-gritty of the digital revolution. Throughout the conference, industry leaders, health providers, and policymakers will come together to explore the opportunities around innovation, better accessibility and efficiency, and the expedition of healthcare into the digital format that the pandemic has catalysed. They will further discuss and offer their insights into the challenges faced by the medical professionals while adapting to novel technologies and the vulnerabilities posed by the COVID situation. The top reasons to attend:

• Best data literacy that gives an edge over the competition
• Leverage the novel digital strategies for optimum patient information and care
• Stay updated on new trends and technologies, and learn how to stay away from fads
• Get access to an interactive community with innovative ideas
• Meet industry stalwarts, all at one interactive platform

The event will feature two eminent spotlight speakers, Michael Kahn, Medical Affairs Operations Leader, Spark Therapeutics and Loreen Brown, Global Head, Patient Support Solutions, Medocity. Several other industry leader and speakers will share their insights and keynotes so that health providers and healthcare professionals can keep up with the acceleration of digital transformation. The COVID scenario has compelled pharma companies to change their working system and immediately transform to digital processing. Attendees will understand and explore the impact and the behavioural changes that have taken effect due to the digital transformation. This interactive session offers lessons on the incorporation of AI, and digital tools into the life science industry. For more details, please visit https://ibn.fm/Q53NY

• FingerMotion (FNGR) a rapidly evolving tech company serving markets in China, announced its financial results for the period Q1 2022
• The company generated $6.00 million in revenue, representing the fourth consecutive quarter of record revenue
• The Telecommunications Products & Services (mobile recharge platform) and the SMS & MMS texting service sectors continued to show strong growth

FingerMotion (OTCQX: FNGR) is a rapidly evolving tech company focused on its core competencies of mobile payment and recharge platform serving markets in China. The company announced its financial results for the period Q1 2022. Sectors that continued to show an upward growth graph are the telecommunications Products & Services (mobile recharge platform) and the SMS & MMS texting service (https://ibn.fm/s84J8). Here is a Financial Summary for the first quarter ended May 31, 2022:

• FingerMotion stood with $789,752 in cash, a working capital surplus of $2,352,502 and a positive shareholders equity of $1,455,643, on May 31, 2021;
• The company generated a revenue of $6.00 million (includes SMS & MMS, Telecommunications Products & Services and Big Data businesses);
• The SMS & MMS businesses recorded a growth in revenue of $1.81 million or 77% compared to Q1 2021;
• The Telecommunications Products & Services businesses recorded a revenue of $1.34 million or 341% compared to Q1 2021;
• Revenues of $98,715 or 198% in Quarter over Quarter (Q4 2021 over Q1 2022) growth in Big Data;
• The quarterly cost of revenue was recorded at $5.38 million which was an increase of $2.93 million or 120% compared to Q1 2021;
• A quarterly loss of $909,506 was reported, which was an increase of $0.33 million or 57% compared to Q1 2021;
• Basic and Diluted loss per share of $0.02;
• The company’s total assets were $8.61 million, Total Current Liabilities were $6.05 million and Total Liabilities were $7.16 million;
• 38,995,160 common shares were issued and outstanding as of May 31, 2021.

Martin Shen, the CEO of FingerMotion said that the first quarter generated $6.00 million in revenue and represented the fourth consecutive quarter of record revenue. If the surge continued, the company revenues may exceed US$24 million for FYE 2022. He further stated that it was the second consecutive quarter of Big Data revenues and they expected it to eventually outpace their other existing revenue streams. With offices in Hong Kong, Shanghai, and New York, FingerMotion is developing additional value-added technologies to expand its user base in China and other regional markets. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Ideanomics’s EV market is expected to grow exponentially, driven by growing public awareness/acceptance and the U.S. administration’s support
• The company plans its expansion moves across three strong EV pillars: vehicles, charging, and energy
• IDEX acquisition of California-based Solectrac reflects the company’s approach to an electric tractor revolution

In 2020, the number of global electric vehicles reached the 10 million mark, with battery electric vehicles (“EVs”) being the main force behind the expansion. The governments of many countries provided fiscal incentives that have acted as a catalyst for the new registration of electric cars (https://ibn.fm/zu2U7). Ideanomics (NASDAQ: IDEX), is a global company focused on revenue-based opportunities in the EV and fintech arenas, geared to leverage the boom in the global EV market. With its three strong pillars of EV (vehicles, charging, and energy) IDEX is shaping the future of energy-driven commercial fleets through its two divisions, Ideanomics Mobility and Ideanomics Capital, focused on cost reduction and environmental sustainability. The company’s businesses operations committed to sustainability and innovations include: 1. US Hybrid Powering fleets in the private and public sectors in the US and other countries, US Hybrid specializes in the design and manufacturing of zero emission powertrain components for electric, hybrid, and fuel cell medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty vehicles throughout the world. 2. WAVE With revenues crossing $7 million in 2020, Wave powers the largest electric mass transit bus fleet in the U.S, at the Antelope Valley Transportation Authority north of Los Angeles with its wireless inductive charging pads 3. Solectrac Ideanomic’s acquisition of this California-based facility reflects the company’s visionary approach towards the electric tractor revolution. This is a pioneering move benefitting farmers and crops, as EV solutions are still unheard of in this segment, while also grabbing a growing slice of agricultural market revenue. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs
• The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program
• Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company
• Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the first four months of this year alone

Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has spent months building up to the launch of several Phase 2a clinical trials for treating select neurological disorders. On July 29, investors will get the opportunity to ask company officers questions about upcoming initiatives in a Q&A that will be part of Tryp’s Fiscal Q3 Investor Day. “I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in a news release about the event (https://ibn.fm/W8nTm). “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.” Tryp’s synthetic psilocybin formulation TRP-8802 is its lead drug candidate and is being developed as a potential treatment for fibromyalgia as well as eating disorders such as binge eating and hypothalamic obesity. Both disorders are targets for Tryp’s Psilocybin-for-Neuropsychiatric Disorders program (“PFN”) that prioritizes maladies with unmet needs based on limitations within the central nervous system Tryp is also developing TRP-8803 as another psilocybin-based drug candidate with a proprietary formulation and method of delivery to improve the patient experience. The Investor Day event will feature a presentation by Tryp’s management team on the PFN program and a discussion on the company’s upcoming milestones. For those who can’t attend the livestream of the event, a replay will be available for 30 days afterward on Tryp’s website. Venture capital investment in the psychedelics sector since 2017 has risen explosively from $1 million to $329 million during the first four months of 2021 alone (https://ibn.fm/p21zW). American psychiatrists as a group have overwhelmingly supported efforts to further use into the use of classic hallucinogens in the treatment of psychiatric disorders, which could have a trickle-down effect for neuropsychiatric issues (https://ibn.fm/DDxec) and efforts by companies like Tryp to attract funding capital. Because the Food and Drug Administration (“FDA”) remains the focal point for assessing the potential for substance abuse and possible adverse events, the establishment of rigorous clinical trials with population sizes and conditions that mirror real-world variables is imperative to advancing novel treatment candidates that may form solutions to heretofore unmet needs (https://ibn.fm/0mzFK). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• 2021 Sequire Blockchain Conference presentations now available on demand
• Conference featured over 15 established and emerging companies across blockchain, cryptocurrency spaces
• Keynote speakers included Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella, Brittany Kaiser

SRAX (NASDAQ: SRAX), a leading financial technology company that helps public companies unlock the power of data through its Sequire SaaS platform, recently hosted the 2021 Sequire Blockchain Conference (https://ibn.fm/fTW6e), featuring over 15 leading blockchain and cryptocurrency-focused companies along with a slew of industry experts, including Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella and Brittany Kaiser. Brock Pierce is a prominent entrepreneur, philanthropist, blockchain pioneer, and 2020 US presidential candidate. Among his many contributions to the blockchain industry was a key role in the development of the first major virtual goods and online gaming marketplace, in addition to the creation of the first series of Initial Coin Offerings (“ICOs”) as a way for emerging blockchain companies to raise capital and increase their public profile. Also featured at the conference was General Electric CIO Maja Vujinovic, who spearheaded the integration of blockchain and AI across a variety of businesses. Joining Vujinovic was Saum Noursalehi, CEO of tZERO – a global leader in developing and commercializing blockchain-based financial technology. BIGtoken Co-Founder and President George Stella brought his digital marketing and data analytics expertise to the conference, in addition to Brittany Kaiser – a best-selling author and globally renowned expert in data protection, blockchain technology, and legislative reform. The conference was hosted on SRAX’s Sequire platform, which serves a growing community of over five million active investors and shareholders across 183 publicly listed corporate subscribers. Since its creation in 2019, Sequire has emerged as a prominent news, educational and networking portal trusted by investors focused on the rapidly growing micro-cap space. “We are excited to kick off our conference series and to provide our Sequire clients a platform to reach a large audience of both retail and institutional investors,” said SRAX CEO and Founder Christopher Miglino (https://ibn.fm/eQFc1). “Community is a very important part of Sequire, and both virtual and in-person events are an integral part of the investor community we are building.” Sequire’s conference series aims to educate investors on growing trends in the microcap space in addition to helping them identify emerging business opportunities. The Sequire Cannabis Conference kicked off the 2021 conference series last April (https://ibn.fm/9MoGQ) and was followed by the highly successful 11th Annual LD Micro Invitational in June (https://ibn.fm/BoVMc). SRAX is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its investor intelligence and communications platform. Available as a SaaS, Sequire helps public companies leverage the power of analytics through unique tools that allow them to track their investors’ behaviors and trends and use those insights to engage current and potential investors across numerous marketing channels. To view replays of the 2021 Sequire Blockchain Conference visit https://blockchain21.mysequire.com. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

5th August 2021 Pricing-Free The Decentralized Finance (“DeFi”) Industry offers a vast set of opportunities and has its set of challenges, with market finance volatility and risks increasing accordingly. The DeFi Conference 2021 is being held on 5th August 2021. This one-day free online event is a great learning and informative platform for businesses, academics, investors, and entrepreneurs to better understand the decentralized finance industry and explore the opportunities that this space offers. The DeFi Conference 2021 is organized by Bitcoin Events, a pioneer events company that hosts world-class bitcoin and blockchain conferences in Africa. The event will bring forth an unparalleled team of DeFi industry leaders and change-makers to share their experiences about how they are shaping the next era of global finance. Why should You attend the DeFi Conference 2021? 

• Connect and engage with 35+ World-Class Speakers and dynamic personas of the DeFi space as they speak about the disruptive products, services, and platforms of the DeFi Industry that they have built over the years, and the challenges surrounding these products.
• The event will showcase 2 tracks with one dedicated to DeFi and the other one to NFTs. These tracks will feature interesting topics on innovative DeFi ideas and the latest developments in the decentralized finance space.
• This conference offers a powerful medium to connect and learn from the reputed industry personnel across a spectrum of industries like insurance, finance, trading, investments, and so on.

This high-impact innovative event will feature two tracks, one about DeFi and the other about NFTs. Attendees can engage with influential DeFi industry leaders as they cover topics on financial inclusion, open finance, and the challenges in compliance, security, adoption, and regulation. New businesses and startups can gain insights from the experience of the industry veterans to develop strategies for their businesses and successful DeFi implementation. The DeFi Industry offers a huge palette of opportunities that industries, corporates, entrepreneurs, and capitalists can leverage. This conference is a viable learning platform for these sectors to gather in-depth financial information regarding the Decentralized finance industry and apply it to their business. Exhibitors will showcase their latest blockchain and cryptocurrency solutions and get a chance to interact with the attendees and establish healthy networking. In this event, like-minded individuals connect and learn about some of the most interesting blockchain use cases from a range of leading industries, international experts, startups in the Blockchain arena. For more information regarding the details of the event, please visit http://bitcoinevents.co.za/defi-conference-2021/.

• CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments
• Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway
• CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the last couple of months, demonstrating the company’s operational, financial, and strategic strengths and continuously de-risking its lead candidate Berubicin clinical program. According to a company press release providing critical operational updates, the company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (“GBM”). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021 (https://ibn.fm/57nx3). GBM is an aggressive type of brain cancer that is often difficult to treat. Most treatments only slow the progression of cancer and reduce the symptoms. Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. The designation will enable more frequent interactions between the FDA and the company, expediting the development and review process for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer (https://ibn.fm/ObyTP). “Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,” he explained. In addition to the success of Fast Track designation and commencing enrollment in the clinical trial, CNS Pharmaceuticals has secured an additional $4.7 million in gross proceeds from the Company’s ATM facility at an average price of $2.32. These proceeds help fund the ongoing clinical programs and have extended the company’s cash runway to Q2 2022. These developments are the latest of multiple achievements the company has reported since its original IPO in November 2019. These achievements include:

• Obtaining orphan drug designation for Berubicin
• Receiving approval of the Investigational New Drug (“IND”) application
• Designing a clinical trial that may support an accelerated pathway to registration
• Manufacturing a clinical supply of Berubicin in both the U.S. and Europe under a dual-track strategy that addressed COVID-related restrictions on imports

“In a mere 18 months from our IPO, our laser focus on this program created a potentially pivotal study now open for enrollment, with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devastating and heretofore incurable disease,” Climaco added. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• The new version of the Fan Pass platform (v2.0) for mobile and desktop is scheduled for release one year after its debut, with new and improved offerings outlined in a new corporate presentation
• Artists and fans both benefit from the updated version, gaining an easy-to-use dashboard that tracks ticket and merchandise sales (for artists) and special access into the lives of the artists (for fans)
• Friendable estimates that if three celebrity partners with 10 million followers each marketed the Fan Pass platform and 1% of those followers subscribed, that would bring 300,000 new subscribers to the artist streaming platform
• A subscription to the Fan Pass platform is $2.99 all-access, and additional PPV events are priced individually on a case-by-case basis

With the first anniversary of Friendable’s (OTC: FDBL)  flagship offering, the Fan Pass platform, drawing near, the company reports a key milestone – 5,000 new sign-ups for the artist streaming platform. The Fan Pass platform was created to give fans exclusive access to the lives of their favorite artists, and artists a virtual stage to earn revenue, engage fans, and above all else, perform. “New artist sign-ups on Fan Pass continue to rise, and as we near completion of our new website and all digital media assets, we expect to also see a significant increase in brand awareness, app downloads, artist sign-ups, and a swarm of fans that will use our app and begin to drive revenue increases for their favorite artists, as well as our business,” commented Robert A. Rositano, Jr., CEO and co-founder of Friendable (https://nnw.fm/lQG3z). (https://ibn.fm/NsSAo). The new milestone in artist sign-ups was announced just days before the Fan Pass platform’s version 2.0 for mobile and web is set to release. The updated version rolls out on July 24, which also marks the artist streaming platform’s one-year anniversary. Along with the new version come many new offerings for both artists and fans, which were laid out in the company’s new corporate presentation. Artists on the streaming platform will gain access to features such as:

• Sound checks to test equipment before going live
• Integrated dashboard – includes comprehensive analytics, tutorials on how to go live, chat support, etc.)
• Mobile streaming capabilities
• Instant artist access
• Live viewer count
• The ability to receive donations/tips from fans directly
• Subscription packages
• Instant dashboard updates (ticket and merchandise sales)
• Custom designed merchandise

Fans using the streaming platform will gain:

• An exclusive look into the everyday lives of favorite musical artists
• Backstage access before, during, and after an event
• Special interviews and one-on-one videos
• Behind-the-scenes view on music videos, films, or photo-shoot sets and green rooms
• Access to custom merchandise

The artist streaming platform is a subscription-based service for fans, costing $2.99 per month all-access. Fans can also purchase tickets to pay-per-view events, priced on a case-by-case basis. Artists will be able to see the revenue they are earning right on the new and improved artist dashboard to be released with version 2.0. “Our metrics show great potential for scale and v2.0 of Fan Pass is designed to provide and allow a solid, scalable infrastructure that is ready to handle the demand we have identified since launch,” Rositano added. “We will continue to keep shareholders up-to-date as we progress along this exciting path of growth.” The revenue brought in by the Fan Pass platform is generated by growing the subscriber base, and offering paid access to streaming events. The company’s presentation points out that if celebrity partners leverage their social following market to Fan Pass, the exposure could be exponential. Three celebrities with 10 million followers provide a social reach of 30 million followers (potentially) for the artist streaming platform. Even if one percent (1%) of these followers were to subscribe, the Fan Pass platform would be looking at 300,000 subscribers, according to Friendable. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://nnw.fm/FDBL http://ibn.fm/FDBL

• New numbers project that cannabis beverage market will reach $2.8 billion by 2025
• Increasing demand for the health and wellness drinks is contributing to market growth
• BevCanna’s scalable, flexible manufacturing process provides white label solutions for third-party companies

A new report that forecasts the cannabis beverage market will grow at 17.85% CAGR by 2025 has companies such as BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) anticipating increased numbers as well (https://ibn.fm/zh9Pa). A leader in the space, BevCanna is looking to leverage its position in the growing market as a white label manufacturer of infused-cannabis beverage brands. According to a recent Million Insights study, the global cannabis beverages market is estimated to reach $2.8 billion by 2025 and is projected to grow at a CAGR of 17.8% from 2019 to 2025. “The increasing demand for the health and wellness drink is boosting the market growth,” the report states. “Additionally, the increasing acceptance of cannabis for medical purposes in various countries is expected to increase the production of cannabis beverages.” The report pointed to cannabis drinks to “help treat cancer, pain and neurological disorders. Further, the increasing interest of consumers for cannabis edible is expected to indirectly drive the cannabis beverage market growth. Consumers are shifting from smoking cannabis to tinctures, chocolates, edibles and other beverages,” the report states. “All these key factors are anticipated to foster the demand for the product in the next few years.” Another insight offered by the report is the rising demand for cannabis drinks from cafes, restaurants, lounges and club as “the changing consumer preference and decline in the sale of alcoholic drinks is increasing beverage consumption.” All these factors combine to fuel the anticipated growth in the expanding cannabis beverage market. Because BevCanna is a diversified health and wellness beverage and natural products company, the company is particularly well qualified to meet the demand for these types of drinks. In addition, the BevCanna team boasts decades of experience creating, branding and distributing wellness and recreational beverages that resonate with consumers on a global scale. Utilizing this unique expertise, BevCanna manufactures its own product lines: Pure Therapy and TRACE. Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (“CBD”) products, throughout North America. BevCanna’s TRACE product line features unique and ancient minerals that offer a broad range of wellness properties including immune function, cognitive performance, and gut health. In addition, the company’s scalable and flexible manufacturing process provides white label solutions for third-party companies looking to enter this promising space with the highest-quality products available. A manufacturer of traditional and cannabis-infused beverage brands, the company is serving a growing roster of white-label clients. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• GTVH has new office space to develop, manage, market all company ventures
• Lavish Entertainment’s goal is to “throw the most epic raves in the world”
• Founder notes spinoff of two companies slated to happen after GTVH completes audited financials

Golden Triangle Ventures (OTC: GTVH) has announced key milestones reached by its entertainment division, which owns Lavish Entertainment Inc. and is doing business as EpicRaves. GTVH president Steffan Dalsgaard provided a summary of the division’s impressive progress in a mid-year letter to shareholders (https://ibn.fm/bikQI). In the letter, Dalsgaard noted significant progress made by the company’s entertainment division, including moving into new office space in Las Vegas and building “a place where we could not only develop, manage, and market all the companies within Golden Triangle Ventures but also have a home for all our in-house concert production equipment so we could organize livestreamed events and highlight the great artists that sign on to our Syndicate Bass Records label.” The letter noted that owning the production, acquiring professional equipment and learning how to operate that equipment were bringing the company closer to its final goal. “Our vision is to throw the most epic raves in the world, and I am so confident that we are going to create events that leave our guests with a true experience unlike anything this city has seen,” said Dalsgaard. “Our very first show back is held on July 23, 2021, at Hard Rock Live in Las Vegas, and we will be highlighting some of the artists that we expect to sign as the first release within our label. This record label is a bit different than most because we will not only be highlighting some very talented musical artists that make experimental and unique bass music, but we will also be highlighting amazing visual artists that will create custom video content on each release we drop.” In addition, Dalsgaard mentioned the company’s focus on building a platform that can monetize and share its events to the world through virtual reality or directly on TV. “This platform is currently being developed by some of the best in the business, and we now have a go-to market strategy that will grow into a platform unlike anything in the world,” Dalsgaard noted. “The first phase is near complete, and we will soon be getting a demonstration of the platform in person.” Dalsgaard also reported that the company’s plan to purchase the Sahara Event Center was, while not guaranteed, at least moving forward. Dalsgaard also alluded to two major projects that he called “the biggest opportunities I have ever worked towards. We are working on patenting both projects globally, and we plan to share full details on them immediately after.” Finally, Dalsgaard provided an update regarding the company’s earlier announcement that Lavish Entertainment and Global Health Services would spin off of Golden Triangle Ventures into their own trading entities and that all the shareholders who owned GTVH by February 19, 2021, would receive a 1:1 dividend in these new entities. The move is slated to happen after Golden Triangle completes its audited financials. “We have retained Malone & Bailey to do full audited financials on our company,” stated Dalsgaard, “and we will move forward to complete this goal once all these acquisitions are in place and the world understands our ultimate vision. Once Global Health Services and Lavish Entertainment spin off, Golden Triangle Ventures will own about 25% of each company in equity, so all our GTVH shareholders indirectly own a piece of both companies, regardless of if you owned our stock prior to the declared dividend date.” Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint-venture with established entities that management can assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH